


In the Claims:

Cancel the preamble and Claims 1-31, and insert therefor


-- WE CLAIM:

32. A method for preventing, reducing, or eliminating side effects or neutralizing the effect of a cancerostatic or immunosuppressive agent administered prophylactically or therapeutically to a patient, comprising administering to the patient a compound having vitamin PP activity or a prodrug thereof.


33. The method of claim 32 where the compound having vitamin PP activity or a prodrug thereof is selected from the group consisting of compounds of formulae II, IIa, IIb, III, IIIa, IIIb, IIIc, IV, IVa, IVb, V, Va, and Vb:




(II)




(IIa)




(IIb)




(III)




(IIIa)



(IIIb)



(IIIb)



where:

a is an integer of 1 through 6;

b is an integer of 1 through 2;

X⁻ is selected from the group consisting of fluoride, chloride, bromide, iodide, hydrogensulfate, mesylate, trifluoromethanesulfonate, tosylate, tetrafluoroborate, dihydrogenphosphate, and acetate;

*R*²¹ is selected from the group consisting of hydrogen, halogen, cyano, alkyl, trifluoromethyl, hydroxyalkyl, hydroxy, alkoxy, alkanoyloxy, alkylthio, aminoalkyl, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, and carboxy;

*R*²² is selected from the group consisting of hydrogen, halogen, alkyl, trifluoromethyl, hydroxyalkyl, hydroxy, alkoxy, alkanoyloxy, aminoalkyl, amino, alkoxycarbonyl, aminocarbonyl, and carboxy;

~~Sus
C2
cont.~~

A⁽ⁱ⁾ and D⁽ⁱ⁾ are independently a saturated or unsaturated optionally substituted aliphatic hydrocarbyl residue, optionally interrupted by a heteroatom or a functional group;


E is a bond or is a heterocyclic residue having one or two ring nitrogen atoms or one ring nitrogen atom and one ring oxygen atom, linked to D⁽ⁱ⁾ and G through a ring nitrogen atom and a ring carbon atom or through two ring nitrogen atoms; and

G is selected from the group consisting of hydrogen, an aliphatic or araliphatic residue, an unsaturated or aromatic monocyclic or polycyclic carbocyclic residue, a saturated, unsaturated, or aromatic monocyclic or polycyclic heterocyclic residue, bonded directly or through a functional group derived from a carbon, nitrogen, oxygen, sulfur, or phosphorus atom,


and the stereoisomers or racemic or non-racemic mixtures of stereoisomers thereof,

and the tautomers thereof when G is a heterocyclic aromatic ring or an aromatic ring substituted by a hydroxy, mercapto, or amino group,


and the pharmacologically acceptable acid addition salts thereof;
 (b) at least one compound selected from the group consisting of compounds of formulae II, IIa, IIb, III, IIIa, IIIb, IIIc, IV, IVa, IVb, V, Va, and Vb:




(II)



(IIa)



(IIb)



where:

a is an integer of 1 through 6;

b is an integer of 1 through 2;

X⁻ is selected from the group consisting of fluoride, chloride, bromide, iodide, hydrogensulfate, mesylate, trifluoromethanesulfonate, tosylate, tetrafluoroborate, dihydrogenphosphate, and acetate;

R²¹ is selected from the group consisting of hydrogen, halogen, cyano, alkyl, trifluoromethyl, hydroxalkyl, hydroxy, alkoxy, alkanoyloxy, alkylthio, aminoalkyl, amino, alkylamino,

*Sub
C2
cont.*

~~dialkylamino, formyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, and carboxy;~~

~~R²² is selected from the group consisting of hydrogen, halogen, alkyl, trifluoromethyl, hydroxyalkyl, hydroxy, alkoxy, alkanoyloxy, aminoalkyl, amino, alkoxycarbonyl, aminocarbonyl, and carboxy;~~

~~R²³ is selected from the group consisting of hydrogen, alkyl, and hydroxyalkyl;~~

~~R²⁴ is selected from the group consisting of alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, and aralkyl;~~

B2

~~R²⁵ is such that the alcohol R²⁵(OH)_a is selected from monovalent linear and branched C₁₋₁₀ alkanols and ω -dialkylaminoalkanols, benzyl alcohol, divalent linear and branched C₂₋₁₀ diols, mono- or divalent C₅₋₇ cycloalkanols, C₅₋₇ cycloalkanediols, C₅₋₇ cycloalkanemethanols, saturated C₅₋₇ heterocyclomethanols, tri-, tetra-, penta-, and hexavalent linear, branched, and cyclic alcohols with 3 to 10 carbon atoms, glycerin, 2,2-bis(hydroxymethyl)-1-octanol, erythritol, pentaerythritol, arabitol, xylitol, sorbitol, mannitol, isosorbitol, tetra(hydroxymethyl)cyclohexanol, and inositol;~~

~~R²⁶ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, dialkylaminoalkyl, and carboxymethyl;~~

~~when b is 1, R²⁷ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, dialkylaminoalkyl, and carboxymethyl;~~

~~when b is 2, R²⁷ is alkylene in which a methylene group is optionally replaced by O, NH, or N-alkyl; and their thioxo analogs, and the acid addition salts or anionic salts thereof; and~~

~~(c) at least one physiologically acceptable carrier.~~

Please add Claims 45 - 49 as follows:

*Mark 103
cont*
B3
45. The composition of claim 41 where:

R^{21} is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} alkyl, trifluoromethyl, C_{1-6} hydroxyalkyl, hydroxy, C_{1-6} alkoxy, C_{2-7} alkanoyloxy, C_{1-6} alkylthio, C_{1-6} aminoalkyl, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, formyl, alkoxycarbonyl, aminocarbonyl, (C_{1-6} alkyl)aminocarbonyl, di(C_{1-6} alkyl)aminocarbonyl, and carboxy;

R^{22} is selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, trifluoromethyl, C_{1-6} hydroxyalkyl, hydroxy, alkoxy, C_{2-7} alkanoyloxy, C_{1-6} aminoalkyl, amino, (C_{1-6} alkoxy)- carbonyl, aminocarbonyl, and carboxy;

R^{23} is selected from the group consisting of hydrogen, C_{1-6} alkyl, and C_{1-6} hydroxyalkyl;

R^{24} is selected from the group consisting of C_{1-6} alkyl, C_{3-6} alkenyl, C_{2-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, and benzyl;

R^{26} is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{3-6} alkoxyalkyl, C_{1-6} aminoalkyl, C_{4-12} dialkylaminoalkyl, and carboxymethyl;

when b is 1, R^{27} is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{3-6} alkoxyalkyl, C_{1-6} aminoalkyl, C_{4-12} dialkylaminoalkyl, and carboxymethyl;

when b is 2, R^{27} is C_{2-10} alkylene in which a methylene group is optionally replaced by O, NH, or N-alkyl.

46. The composition of claim 41 where the compound having vitamin PP activity or a prodrug thereof is selected from the group consisting of nicotinic acid, nicotinamide, and their pharmaceutically acceptable ester and amide derivatives, anionic, quaternary, and addition salts, N-oxides, and analogous thioxo derivatives, their isomers, and prodrugs thereof.

Mark 41

47. The composition of claim 46 where the compound having vitamin PP activity or a prodrug thereof is selected from the group consisting of nicotinic acid, nicotinamide, and mixtures thereof.

Mark 44

48. The composition of claim 46 where the compound having vitamin PP activity or a prodrug thereof is tryptophan.

B3

49. The composition of claim 41 where the cancerostatic or immunosuppressive agent is selected from the group consisting of N-[2-(1-benzylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl) propionamide;

N-[2-[1-(2-phenylethyl)piperidin-4-yl]ethyl]-3-(pyridin-3-yl)- propionamide;

N-[2-[1-(4-phenylbutyl)piperidin-4-yl]ethyl]-3-(pyridin-3-yl)- propionamide;

N-[2-[1-(4-hydroxy-4-phenylbutyl)piperidin-4-yl]ethyl]- 3-(pyridin-3-yl)propionamide;

N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)- propionamide,

N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)- propionamide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)- propionamide;

N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide; N-[4-[1-(2-phenylethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)- acrylamide;

N-[4-[1-(4-biphenylmethyl)piperidin-4-yl]butyl]- 3-(pyridin-3-yl)acrylamide;

N-[4-[1-(1-naphthylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)- acrylamide;

N-[4-[1-(9-anthrylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)- acrylamide;

N-{4-[1-(cyclohexylphenylmethyl)piperidin-4-yl]butyl}-
3-(pyridin-3-yl)acrylamide;
N-{4-[1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperidin-
4-yl]butyl}-3-(pyridin-3-yl)acrylamide;
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)-
acrylamide;
N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)-
acrylamide;
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)-
acrylamide;
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)-
acrylamide;
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-
2,4-pentadienic acid amide;
N-(4-{1-[bis(4-fluorophenyl)methyl]piperidin-4-yl}butyl)-
3-(pyridin-3-yl)acrylamide;
N-(4-{1-[bis(2-chlorophenyl)methyl]piperidin-4-yl}butyl)-
3-(pyridin-3-yl)acrylamide;
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(2-fluoro-
pyridin-3-yl)acrylamide;
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(6-fluoro-
pyridin-3-yl)acrylamide;
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-
acrylamide;
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-
acrylamide dihydrochloride;
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-
acrylamide methanesulfonate;
N-[4-(1-acetyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;
N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-
propionamide;

N-[4-(1-diphenylacetyl piperidin-4-yl)butyl]-3-(pyridin-3-yl)-propionamide;
N-{4-[1-(9-oxo-9H-fluoren-4-carbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;
N-[4-(1-methylsulfonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-propionamide;
N-{4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;
N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;
N-(4-{1-[bis(2-chlorophenyl)methyl]piperidin-4-yl}butyl)-3-(pyridin-3-yl)propionamide;
B3
N-{4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;
N-{4-[1-(9H-fluoren-9-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-propionamide;
N-{4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;
N-{4-[1-(1-naphthylaminocarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;
N-{4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;
N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(2-fluoropyridin-3-yl)propionamide;
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(5-fluoropyridin-3-yl)propionamide;
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2-fluoro-3-(pyridin-3-yl)propionamide;
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2,2-difluoro-3-(pyridin-3-yl)propionamide;

See PX C

N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)-propionamide;

N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)-propionamide;

N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-5-(pyridin-3-yl)-pentanoic acid amide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-pentanoic acid amide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-N-hydroxy-3-(pyridin-3-yl)propionamide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2-hydroxy-3-(pyridin-3-yl)propionamide;

B3

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-hydroxy-3-(pyridin-3-yl)propionamide;

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-propionamide;

N-[4-(1-methylsulfonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-acrylamide;

N-[4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

N-[4-[1-(1-naphthylaminocarbonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

N-[4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-4-yl]-butyl]-3-(pyridin-3-yl)-acrylamide;

N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1-acetyl piperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1-diphenylacetyl)piperidin-4-yl]-butyl]-3-(pyridin-3-yl)-acrylamide;
N-[4-[1-(3,3-diphenylpropionyl)piperidin-4-yl]-butyl]-3-(pyridin-3-yl)acrylamide;
N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;
N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;
N-[4-[1-(9-oxo-9H-fluoren-4-ylcarbonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;
N-[4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]-butyl]-3-(pyridin-3-yl)acrylamide;
N-[4-[1-(phenylpyridin-4-ylmethyl)piperidin-4-yl]-butyl]-3-(pyridin-3-yl)acrylamide;
N-[4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperidin-4-yl]-butyl]-3-(pyridin-3-yl)acrylamide;
N-[4-[1-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)piperidin-4-yl]-butyl]-3-(pyridin-3-yl)acrylamide;
N-[7-(1-diphenylmethyl)piperidin-4-yl]heptyl]-3-(pyridin-3-yl)-acrylamide;
N-[8-(1-diphenylmethyl)piperidin-4-yl]octyl]-3-(pyridin-3-yl)-acrylamide;
N-[3-(1-diphenylmethyl)piperidin-4-yloxy]propyl]-3-(pyridin-3-yl)-acrylamide;
N-[3-(1-benzyl)piperidin-4-yloxy]propyl]-3-(pyridin-3-yl)-acrylamide;
N-[2-(1-diphenylmethyl)piperidin-4-yl]ethyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;
N-[4-(1-diphenylmethyl)piperidin-4-yl]butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;
N-[5-(1-diphenylmethyl)piperidin-4-yl]pentyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;
N-[6-(1-diphenylmethyl)piperidin-4-yl]hexyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;

N-[4-(4-diphenylmethylpiperazin-1-yl)-3-hydroxybutyl]-
3-(pyridin-3-yl)acrylamide;
N-[3-(4-diphenylmethylpiperazin-1-yl)propoxy]-3-(pyridin-3-yl)-
acrylamide;
N-[4-(4-diphenylmethylpiperazin-1-yl)-4-oxobutyl]-
3-(pyridin-3-yl)acrylamide;
N-[3-(4-diphenylmethylpiperazin-1-sulfonyl)propyl]-
3-(pyridin-3-yl)acrylamide;
N-{2-[2-(4-diphenylmethylpiperazin-1-yl)ethoxy]ethyl}-
3-(pyridin-3-yl)acrylamide;
N-(4-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}but-2-enyl)-
3-(pyridin-3-yl)acrylamide;
B3
N-(4-{4-[(4-carboxyphenyl)phenylmethyl]piperazin-1-yl}butyl)-
3-(pyridin-3-yl)acrylamide;
N-(4-{4-[(4-aminophenyl)phenylmethyl]piperazin-1-yl}butyl)-
3-(pyridin-3-yl)acrylamide;
N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-
2-(pyridin-3-yloxy)acetamide;
N-{5-[4-(9H-fluoren-9-yl)piperazin-1-yl]pentyl}-3-(pyridin-3-yl)-
acrylamide;
N-{6-[4-(9H-fluoren-9-yl)piperazin-1-yl]hexyl}-3-(pyridin-3-yl)-
acrylamide;
3-(pyridin-3-yl)-N-{4-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)-
piperazin-1-yl]butyl}acrylamide;
3-(pyridin-3-yl)-N-{4-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)-
piperazin-1-yl]butyl}acrylamide;
N-{4-[4-{naphthalen-1-yl}piperazin-1-yl]butyl}-3-(pyridin-3-yl)-
acrylamide;
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)-
propionamide;
N-[5-(4-biphenyl-2-ylpiperazin-1-yl)pentyl]-3-(pyridin-3-yl)-
acrylamide;

N-[6-(4-biphenyl-2-ylpiperazin-1-yl)hexyl]-3-(pyridin-3-yl)-acrylamide;
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-2-(pyridin-3-yloxy)-acetamide;
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;
N-{5-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-piperazin-1-yl]pentyl}-3-(pyridin-3-yl)acrylamide;
N-{6-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-piperazin-1-yl]hexyl}-3-(pyridin-3-yl)acrylamide;
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-piperazin-1-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic amide;
N-{4-[4-(6,11-dihydridobenzo[b,e]oxepin-11-yl)piperazin-1-yl]-butyl}-3-(pyridin-3-yl)propionamide;
N-{2-[4-(6,11-dihydridobenzo[b,e]thiepin-11-yl)piperazin-1-yl]-ethyl}-3-(pyridin-3-yl)acrylamide;
N-[4-(4-diphenylacetyl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)-acrylamide;
N-[4-(4-benzoylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;
N-{4-[4-(2-aminobenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;
N-{4-[4-(4-carboxybenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;
N-{4-[4-(biphenyl-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;
N-{4-[4-(9-oxo-9H-fluoren-4-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;
N-{4-[4-(furan-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;
N-{4-[4-(naphthalen-1-ylaminocarbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;

*Not
Claimed*

N-{4-[4-(diphenylaminocarbonyl)piperazin-1-yl]butyl}-
3-(pyridin-3-yl)acrylamide;
N-{4-[4-(naphthalen-2-sulfonyl)piperazin-1-yl]butyl}-
3-(pyridin-3-yl)acrylamide;
N-[4-(4-diphenylphosphinonylpiperazin-1-yl)butyl]-
3-(pyridin-3-yl)acrylamide;
N-[4-(4-biphenyl-2-yl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)-
acrylamide;
N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-
acrylamide;
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-
1-yl]butyl}-3-(pyridin-3-yl)acrylamide;
B3
N-[4-(4-phenylpiperidin-1-yl)-butyl]-3-(pyridin-3-yl)acrylamide;
N-{4-[4-(1H-indol-3-yl)piperidin-1-yl]butyl}-3-(pyridin-3-yl)-
acrylamide;
N-{4-[4-(2-oxo-2,3-dihydrobenzimidazol-1-yl)piperidin-1-yl]-
butyl}-3-(pyridin-3-yl)acrylamide;
N-[4-(4-benzotriazol-1-yl)piperidin-1-yl]butyl]-3-(pyridin-3-yl)-
acrylamide;
N-{4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}-
2-(pyridin-3-yloxy)acetamide;
N-[4-(4,4-diphenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)-
acrylamide;
N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)-
piperidin-1-yl]butyl}-3-(pyridin-3-yl)propionamide
dihydrochloride semi-isopropanol;
N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)-
piperidin-1-yl]butyl}-5-(pyridin-3-yl)pentanamide;
N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)-
piperidin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;
N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)-
piperidin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;

N-[4-(4-diphenylphosphinoyloxy)piperidin-1-yl]butyl]-
3-(pyridin-3-yl)acrylamide;
N-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)butyl]-3-(pyridin-3-yl)-
acrylamide;
N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-
3-(pyridin-3-yl)acrylamide;
N-[4-(2,6-dioxo-4-phenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)-
acrylamide;
N-[4-(1,3-dioxo-4,5,6,7-tetraphenyl-1,3-dihydroisoindol-2-yl)-
butyl]-3-(pyridin-3-yl)acrylamide;
N-[4-(3-benzyl-2,4,5-trioxoimidazolidin-1-yl)butyl]-
3-(pyridin-3-yl)acrylamide;
B3
N-[4-(1,3,10-trioxo-1,4,5,6,10,10a-hexahydroacenaphtho[1,8a-c]-
pyrrol-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;
N-[4-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)butyl]-
3-(pyridin-3-yl)acrylamide;
N-[4-(2,5-dioxo-3-phenyl-2,5-dihydropyrrol-1-yl)butyl]-
3-(pyridin-3-yl)acrylamide;
N-[3-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)propyl]-
3-(pyridin-3-yl)acrylamide;
N-[4-(3-pyridin-3-ylacryloylamino)butyl]-2,3:5,6-dibenzo-
bicyclo[2.2.2]octan-7,8-dicarboximide;
N-[4-(5-benzyliden-2,4-dioxothiazolidin-3-yl)butyl]-
3-(pyridin-3-yl)acrylamide;
N-[4-(4-benzyl-2,6-dioxopiperazin-1-yl)butyl]-3-(pyridin-3-yl)-
acrylamide;
N-[6-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)hexyl]-
3-(pyridin-3-yl)acrylamide;
N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-
3-(pyridin-3-yl)propionamide;
N-[4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)butyl]-3-(pyridin-3-yl)-
acrylamide;

B3

N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-
3-(1-oxopyridin-3-yl)acrylamide;
N-[6-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)hexyl]-
3-(pyridin-3-yl)acrylamide;
N-[2-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)ethyl]-
3-(pyridin-3-yl)acrylamide;
N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-
3-(pyridin-3-yl)acrylamide;
N-[8,8-bis(4-fluorophenyl)octyl]-3-(pyridin-3-yl)acrylamide
hydrochloride;
N-[6-(3,3-diphenylureido)hexyl]-3-(pyridin-3-yl)acrylamide;
N-[4-(1-phenyl-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)butyl]-
3-(pyridin-3-yl)acrylamide;
N-(8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;
N-(8-hydroxy-8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;
N-[4-(3,3-diphenylureido)butyl]-3-(pyridin-3-yl)acrylamide;
N-[4-(1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(pyridin-3-yl)-
acrylamide;
N-[6-(10,11-dihydrodibenzo[b,f]azepin-5-ylcarbonylamino)hexyl]-
3-(pyridin-3-yl)acrylamide;
3-(pyridin-3-yl)-N-[6-tosylaminohexyl]acrylamide;
N-[4-(1,1-dioxo-1-thia-2-azaacenaphthylen-2-yl)butyl]-3-(pyridin-
3-yl)acrylamide;
N-(6-hydroxy-6,6-diphenylhexyl)-3-(pyridin-3-yl)acrylamide;
N-(6,6-diphenylhex-5-enyl)-3-(pyridin-3-yl)acrylamide;
N-[4-(4,5-diphenylimidazol-1-yl)butyl]-3-(pyridin-3-yl)-
acrylamide;
N-[4-(trans-2-phenylcyclopropylcarbonylamino)butyl]-
3-(pyridin-3-yl)acrylamide;
N-(5-hydroxy-5,5-diphenylpentyl)-3-(pyridin-3-yl)acrylamide;
N-(7-phenylheptyl)-3-(pyridin-3-yl)acrylamide;
N-(4-diphenylacetylaminobutyl)-3-(pyridin-3-yl)acrylamide;
N-[4-(benzhydrylamino)butyl]-3-(pyridin-3-yl)acrylamide; and